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Abstract
Advances in understanding the mechanisms of tumour-
induced immunosuppression have led to the development of 
immune-checkpoint inhibitors in cancer patients, including 
those with renal cell carcinoma (RCC). The optimal combination 
between immunotherapy and targeted agents (as well as the 
possible favourable sequential therapy of these two classes 
of drugs) remains an open question at this moment. Several 
trials are currently underway to assess the combination of 
anti-programmed-death 1 (PD-1) or anti-PD-ligand(L)1 agents 
with other immunotherapies or with anti-vascular endothelial 
growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs). 
In this editorial, we described the results of the most recent 
clinical trials on the use of immunotherapies in RCC and the 
emerging data on the research for reliable biomarkers of tumour 
response in this setting. In addition, we have focused on the role 
of the gut microbiome and tumour microenvironment in the 
development of future therapeutic strategies for RCC patients. 
Keywords: immunocheckpoint inhibitors, immunotherapy, 
PD-1, renal cell carcinoma, tyrosine kinase inhibitors.
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Introduction
Less than ten years ago, there were only a few drugs with 
demonstrated clinical efficacy in the management of metastatic 
renal cell carcinoma (mRCC) but without significant impact on 
clinical outcomes. However, in recent years, the approval of 
several agents has revolutionized treatment. Indeed, every new 
drug approved has provided a further step in the improvement 
of patient survival. Consequently, it is important to have a 
better understanding of tumour biological features as well as 
genetic assessment. Thus, we have discovered that renal cell 
carcinoma (RCC) involves a very large spectrum of tumours. 
Each of them is composed of a different spectrum of mutations 
and with different clinical behaviour. Clear cell RCC (ccRCC) 
accounts for approximately 75% of kidney cancer. In contrast, 
the other 25% of kidney cancer is classified as nonclear cell 
RCC (nccRCC). Of this last subgroup of tumours, the World 
Health Organization recognized a broad spectrum of over a 
dozen histopathological entities in 2016. Papillary renal cell 
carcinoma (pRCC) and chromophobe RCC (chRCC) are the most 
frequent subtypes of nccRCC; whereas, medullary, translocation 
and collecting duct RCC represent an infrequent diagnosis 
[1]. Each tumour subtype presents a specific and complex 
spectrum of gene and molecularly altered pathways resulting 
in a heterogeneous mixture of malignancies associated with 
different morphology, immunohistochemical features, clinical 
behaviour and prognosis. 
Our growing understanding of the molecularly altered 
pathways related to cancer has led to the development of 
new classes of drugs that have rapidly replaced the first 
immunotherapies such as interleukin (IL)-2 and interferon-alfa 
(IFN-alfa) as the standard of care for RCC patients. Angiogenesis, 
the hallmark of RCC, is the first final target of several tyrosine 
kinase inhibitors (TKIs) (sunitinib, axitinib, sorafenib and 
pazopanib). After angiogenesis, the finding that deregulation 
of the PI3K–Akt–mTOR pathway, activated at different levels 
of the signalling cascade, drives RCC progression has led to 
the development of two mTOR inhibitors: everolimus and 
temsirolimus. Recently, the mesenchymal-epithelial transition 
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(MET) and multityrosine kinases inhibitor cabozantinib has 
been included in clinical practice. 
These drugs have led to an improvement in overall survival (OS) 
(sunitinib, pazopanib and cabozantinib) and in progression-
free survival (PFS) (sunitinib, axitinib, cabozantinib, sorafenib, 
pazopanib, everolimus and temsirolimus), which was the endpoint 
of interest for FDA approval, until recently. All of these drugs 
showed a good safety profile combined with remarkable clinical 
activity in a disease that has always been difficult to treat [2−10].
Immune-checkpoint inhibitors 
Although these drugs have significantly changed the course 
of this disease, the latest class of agents, the immune-
checkpoint inhibitors, are predicted to provide further benefit. 
Programmed death receptor 1/programmed death receptor 
ligand 1 (PD-1/PD-L1) and cytotoxic T lymphocytes antigen 
4 (CTLA-4) inhibitors target specific pathways related to the 
immune response, which are often hyperactivated by tumour 
cell interaction. By inhibiting these pathways, immune-
checkpoint inhibitors could reactivate a specific immune 
response against tumour cells. The observation that RCC is 
related to a high mutation load and so maybe to high antigen 
expression has led to these drugs being tested at different 
stages of the disease. CheckMate 025 was the first large phase 
III clinical trial comparing the PD-1 inhibitor, nivolumab, to 
everolimus in patients with locally advanced or metastatic 
RCC who had progressed to at least one VEGF/VEGFR inhibitor. 
This study met its primary endpoint showing an OS benefit in 
patients receiving nivolumab. Furthermore, patients treated 
with immunotherapy showed a higher overall response rate 
(ORR) compared to everolimus with a considerable percentage 
of these achieving long-lasting response [11]. It is not surprising 
that the important results achieved in this trial led researchers 
to explore immunotherapy in other settings such as adjuvant/
neoadjuvant stage and as first-line therapy [12–14]. Of note, 
Motzer and colleagues recently reported results of CheckMate 
214, a phase III trial that tested the combination of ipilimumab 
and nivolumab over sunitinib in previously untreated patients 
with intermediate/poor risk (according to IMDC) metastatic 
or locally advanced ccRCC. The combination resulted in a 
significant OS benefit (median overall survival not reached 
versus 26.0 months with sunitinib, hazard ratio [HR] 0.63) in this 
population of patients. In addition, ORR was significantly better 
in the combination arm (42% with 9% of CR) compared to 
sunitinib (27% with 1% of CR).
Regarding this last point, two different strategies have been 
adopted.
Combination of an immune-checkpoint 
inhibitor and a VEGF inhibitor 
The combination of an immune-checkpoint inhibitor and 
a VEGF inhibitor has been evaluated in phase II trials. In the 
IMmotion150 study, 305 patients with locally advanced/mRCC 
and untreated RCC were randomized to receive atezolizumab 
(an anti-PD-L1 inhibitor) plus bevacizumab, atezolizumab alone 
or sunitinib. The combination arm resulted in a longer PFS 
compared to atezolizumab (6.1 months) and sunitinib arms 
with a higher percentage ORR in the combination arm. Of note, 
patients with PD-L1 positive expression (≥1%) showed a longer 
PFS (14.7 months) and higher ORR (46%) in the atezolizumab 
monotherapy arm [15].
The combination of two immune-checkpoint inhibitors has 
been recently tested in a large phase III trial: CheckMate 214. 
In this study, patients were randomized to receive nivolumab 
(anti-PD-1) plus ipilimumab (anti-CTLA-4) or sunitinib as first-
line therapy. At the 2017 ESMO Conference, Escudier presented 
primary results after 17.5 months of follow-up showing that the 
ipilimumab plus nivolumab combination resulted in higher ORR 
and CR in intermediate/poor-risk patients. Of note, patients 
with intermediate/poor-risk disease and PD-L1 expression ≥1% 
showed higher ORR and PFS compared to sunitinib; whereas, 
patients with favourable category of risk (which showed lower 
PD-L1 expression) showed a longer PFS and a higher ORR with 
sunitinib [16].
These encouraging results may only be the ‘tip of the iceberg’ 
and could suggest that we are entering a new era for the 
management of mRCC. Nonetheless, even if immunotherapy 
represents a new hope for patients with mRCC, the relatively 
older targeted therapy is far from being abandoned. In other 
words, although CheckMate 025 showed that nivolumab 
is better than everolimus, there are other agents that are 
extremely effective after VEGF/VEGFR inhibitors progression; 
thus, the decision for second-line treatment should be weighed 
on the basis of the clinical outcome pursued as well as patient 
preference and drug toxicity profile. Immunotherapy has 
shown very interesting result in first-line therapy. Looking to 
CheckMate 214 results, it is probable that this positive effect 
could be restricted in patients with specific clinical features 
such as intermediate/poor-risk disease; whereas, patients 
with a favourable profile could benefit more from a standard 
treatment [14]. This would suggest that the worst clinical 
profile of the disease could be related to a high mutation load 
of tumour cells resulting in a higher antigen expression. In 
addition, preliminary data seem to indicate that these patients 
present a higher percentage of tumours with positive PD-
L1 expression. However, to date, no mature data about the 
role of immunotherapy in favourable risk patients have been 
released. Furthermore, in an exploratory analysis of CheckMate 
214, immunotherapy also showed a not-to-be-ignored clinical 
activity in patients with favourable risk (CR 11 versus 6%) even  
if the same combination was associated with a worse ORR  
(29 versus 52%) compared to sunitinib. Future studies will help 
us to better understand the role of PD-L1 as a prognostic and 
predictive response factor because, to date, we have strongly 
diverging information. Indeed, a meta-analysis of six published 
studies revealed that a higher level of PD-L1 expression 
increased the risk of death by representing, therefore, a 
negative prognostic factor [17]. Different to what was expected, 
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At present, we do have full knowledge of the underlying 
mechanisms of immune-checkpoint inhibitors-induced 
tumour response. To address this issue, Wei and 
colleagues investigated the effects of anti-PD-1 and 
anti-CTLA-4 inhibitors in human melanoma and murine 
tumour models [30]. They first revealed that these agents 
are able to target distinct tumour-infiltrating T-cell 
subpopulations. In particular, PD-1 blockade promotes the 
expansion of specific exhausted-like CD8 T-cell populations; 
whereas, CTLA-4 blockade induces both an ICOS+ Th1-like 
CD4 effector subset and exhausted-like CD8 T cells [30]. 
the improved OS with nivolumab was not correlated with PD-L1 
expression in CheckMate 025; whereas, patients with positive 
PD-L1 expression seemed to show more clinical benefit from 
immune-checkpoint inhibitors in IMmotion150 and CheckMate 
214 (Table 1). 
Future challenges
The complex interplay of inflammatory mediators and 
signalling pathways is absolutely crucial for RCC development 
and response to therapy [18−22] (Figure 1). Neutrophils, 
lymphocytes and macrophages have been implicated in 
promoting tumour angiogenesis and metastatic spread, 
as well as in the formation of pre-metastatic niches and in 
primary and acquired drug resistance [18−22]. In this scenario, 
the checkpoint molecules have gained wide interest since 
the introduction of anti-CTLA-4 and anti-PD-1/PD-L1 agents 
into daily clinical practice [23]. Beyond PD-1 and CTLA-4, a 
variety of molecules are emerging as potential therapeutic 
immunotargets in RCC [24]. This list includes the V-domain 
immunoglobulin containing suppressor of T-cell activation 
(VISTA), which has been recently shown to exert its inhibitory 
activity by acting as a ligand on antigen presenting cells 
(APCs) and as a receptor on T cells [25−27], chemokine 
receptors [28], the soluble lymphocyte-activation gene-3 
(LAG-3), 4-1BB, B and T lymphocyte attenuator (BTLA) and 
OX40 (CD134) [29].
Table 1. Results obtained in trials exploring immune-checkpoint inhibitors in metastatic/locally advanced RCC.  
Study name
Experimental arm
Comparator arm
Setting N
ITT
N
PD-L1+
OS
ITT
HR OS
PD-L1+
PFS
ITT
HR PFS
PD-L1+
HR ORR
ITT
ORR
PD-L1+
CR
CHECKMATE 025
Nivolumab Previously 
treated 
patients 
with locally 
advanced or 
mRCC 
410 94 25.0 0.73 21.8 4.6 0.88 NR NR 25% NR 1%
Everolimus 411 87 19.6 18.8 4.4 NR 5% NR <1%
IMMOTION150
Atezolizumab + 
bevacizumab
Untreated 
patients 
with locally 
advanced or 
mRCC 
101 164 NR NR NR NR NR NR NR 32% 46% NR
Atezolizumab 103 NR NR NR NR 25% 28% NR
Sunitinib 101 NR NR NR NR 29% 27% NR
CHECKMATE 214
Ipilimumab + 
nivolumab 
Untreated 
patients 
with locally 
advanced or 
mRCC
550 204 NR NR NR 11.6 0.82 22.8* 0.48 NR 58%* 9.4%*
Sunitinib 546 224 NR NR NR 8.4 5.9* NR 25%* 1.2%*
CR, complete response; NR, not reported; ORR, overall response rate; OS, overall survival; PFS, progression-free survival. 
*Intermediate/poor-risk patients with PD-L1 expression ≥1%.
Figure 1. Clear cell renal cell carcinoma (ccRCC) 
with chronic inflammation.
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This evidence strongly supports the results of different trials 
exploring this combination therapy in different diseases 
and favours the combined use of current and future 
checkpoint inhibitors in cancer patients, which seems to be 
characterized by a good tolerable safety profile [14,31–33]. 
The results obtained in recent years have raised enormous 
enthusiasm in cancer researchers, aimed at identifying, 
isolating and validating biomarkers associated with the 
dynamics of the tumour environment and the therapeutic 
response [17,34,35]. Indeed, tumour responsiveness varies 
according to the mutation load and the expression of 
immunotargets in the tumour environment, which is variable 
in the different phases of RCC development and progression 
[36]. Based on this evidence, assessing the expression of PD-1/
PD-L1 or other emerging immunotargets only at the diagnosis 
of metastatic disease may not reflect tumour dynamicity. 
To improve the feasibility and reduce the clinical impact of 
re-biopsy, assessing biomarkers on circulating tumour cells 
(CTCs) or exosomes [37] may represent a noninvasive strategy 
that can be performed several times during cancer therapy 
to reflect changes that occurred in the tumour environment. 
The early identification of validated biomarkers will be crucial 
to definitively carry immunotherapy into the era of precision 
medicine and to optimize the cost-effectiveness of these 
agents in cancer patients [38,39]. 
More recently, Routy and colleagues revealed that primary 
resistance to immune-checkpoint inhibitors can be correlated 
with abnormal gut microbiome composition [40]. In this 
study, the effectiveness of PD-1 blockade was enhanced by 
transplanting faecal microbiota from responder cancer patients 
into germ-free or antibiotic-treated mice [40], thus representing 
another step on the way to personalized and precision 
immunotherapy in cancer patients.
Another factor that is fundamental to improve the efficacy 
of immunotherapy in RCC patients is a better understanding 
of the immunological effects of TKIs and mTOR inhibitors 
[18,41]. Indeed, these agents can indirectly exert their 
anti-tumour activity by targeting immune cells in the RCC 
microenvironment [18], and this should be considered to 
combine or sequence them with currently available and future 
immunotherapies. In this regard, sunitinib has been shown 
to inhibit the colony forming units (CFUs) driven by GM-CSF 
and FLT3 ligand (FLT3L) [42] as well as dendritic cell antigen 
presentation [40] (by decreasing the secretion of cytokines 
and the expression of MHC and CD1a molecules), to suppress 
the myeloid-derived suppressor cells (MDSCs, involved in 
RCC progression and drug resistance), to enhance tumour 
cell sensitivity to natural killer (NK) cell killing [43] and to 
reduce the total count of CD3 and CD4 T cells and regulatory 
T cells [44,45]. On the other hand, pazopanib showed lower 
inhibitory potency and affinity against FLT3 and c-kit compared 
to sunitinib [46]. Interestingly, we previously showed that 
axitinib can increase the surface NKG2D ligand expression, 
thus promoting NK cell recognition and degranulation in 
A-498 RCC cells in a ROS-dependent manner [47]. At present, 
little evidence is available on the immunomodulatory effects 
of cabozantinib and lenvatinib, both of which were recently 
introduced into RCC clinical practice. With regard to the 
association between immunotherapy and TKIs, the association 
between atezolizumab and both bevacizumab [48] and 
cabozantinib [49] as well as pembrolizumab and axitinib [50] 
has shown promising results in terms of clinical activity and 
safety profile – thus justifying the planning of several different 
Table 2. Ongoing phase III clinical trials testing the association between immunotherapy and TKIs.
Trial Treatment arms n Setting Estimated primary completion 
date
NCT02811861 Sunitinib
versus
lenvatinib + everolimus
versus
lenvatinib + pembrolizumab
735 First line October 2019
NCT02684006 Avelumab + axitinib
versus
sunitinib
830 First line December 2018
NCT03141177 Nivolumab + cabozantinib
versus
sunitinib
630 First line September 2019
NCT02420821 Atezolizumab + bevacizumab versus
sunitinib
915 First line July 2020
NCT02853331 Pembrolizumab + axitinib
versus
sunitinib
840 First line January 2020
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large trials exploring these associations in metastatic/locally 
advanced RCC (Table 2). 
Conclusions
Optimizing the combination of immunotherapy and target 
agents, as well as the possible favourable sequence of 
treatment between these two classes of drugs, remains as open 
questions at this moment. We have only few data provided 
from IMmotion150, which demonstrated that association 
between a PD-L1 inhibitor and bevacizumab is feasible with 
a satisfactory safety profile. However, we do not know if this 
association results in an effective clinical benefit from our 
patients. Finally, it is important to observe that all the cited 
studies explored immunotherapy in patients with ccRCC  
and the role of immunotherapy still remains unknown in 
nccRCC. 
There are several questions that need to be answered. It is 
undeniable that immunotherapy represents a revolution for 
the management of RCC resulting in a dynamic and evolving 
scenario. Future studies will increase our knowledge about the 
role of immunotherapy in this no-more orphan disease.
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